4D MOLECULAR THERAPEUTICS

4d-molecular-therapeutics-logo

4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

#SimilarOrganizations #People #Financial #Website #More

4D MOLECULAR THERAPEUTICS

Social Links:

Industry:
Biotechnology Genetics

Founded:
2013-01-01

Address:
Emeryville, California, United States

Country:
United States

Website Url:
http://www.4dmoleculartherapeutics.com

Total Employee:
11+

Status:
Active

Contact:
(510) 505-2680

Total Funding:
175 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Content Delivery Network Google Universal Analytics


Similar Organizations

biomarin-pharmaceutical-logo

BioMarin Pharmaceutical

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

bluebird-bio-logo

Bluebird Bio

Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.

editas-medicine-logo

Editas Medicine

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.

fulgent-therapeutics-logo

Fulgent Therapeutics

Fulgent Therapeutics, LLC is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics.

moderna-therapeutics-logo

Moderna Therapeutics

Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.

ngm-biopharmaceuticals-logo

NGM Biopharmaceuticals

NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.

purigen-biosystems-logo

Purigen Biosystems

Purigen Biosystems' innovative products offer a truly transformative automated solution for DNA and RNA purification.

voyager-therapeutics-logo

Voyager Therapeutics

Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.


Current Advisors List

david-alexandre-gros_image

David-Alexandre Gros Senior Executive Advisor @ 4D Molecular Therapeutics
Advisor
2018-02-01

susannah-gray_image

Susannah Gray Board Member @ 4D Molecular Therapeutics
Board_member
2020-08-01

Current Employees Featured

peter-francis_image

Peter Francis
Peter Francis Chief Scientific Officer & Therapeutic Area Head, Ophthalmology @ 4D Molecular Therapeutics
Chief Scientific Officer & Therapeutic Area Head, Ophthalmology
2020-02-01

fred-kamal_image

Fred Kamal
Fred Kamal Chief Operating Officer & Chief Technical Officer @ 4D Molecular Therapeutics
Chief Operating Officer & Chief Technical Officer
2020-02-01

theresa-janke_image

Theresa Janke
Theresa Janke Chief Strategic Officer & Co-founder @ 4D Molecular Therapeutics
Chief Strategic Officer & Co-founder

david-kirn_image

David Kirn
David Kirn Co-Founder, President & CEO @ 4D Molecular Therapeutics
Co-Founder, President & CEO
2013-04-01

Founder


david-kirn_image

David Kirn

david-schaffer_image

David Schaffer

theresa-janke_image

Theresa Janke

Stock Details


Company's stock symbol is NASDAQ:FDMT

Investors List

longevity-vision-fund_image

Longevity Vision Fund

Longevity Vision Fund investment in Series C - 4D Molecular Therapeutics

miraeasset-financial-group_image

MiraeAsset Financial Group

MiraeAsset Financial Group investment in Series C - 4D Molecular Therapeutics

bvf-partners_image

BVF Partners

BVF Partners investment in Series C - 4D Molecular Therapeutics

pappas-capital_image

Pappas Capital

Pappas Capital investment in Series C - 4D Molecular Therapeutics

chiesi-ventures_image

Chiesi Ventures

Chiesi Ventures investment in Series C - 4D Molecular Therapeutics

viking-global-investors_image

Viking Global Investors

Viking Global Investors investment in Series C - 4D Molecular Therapeutics

quad-asset-management_image

QUAD Investment Management

QUAD Investment Management investment in Series C - 4D Molecular Therapeutics

pfizer-venture-investments_image

Pfizer Venture Investments

Pfizer Venture Investments investment in Series C - 4D Molecular Therapeutics

berkeley-catalyst-fund-bcf_image

Berkeley Catalyst Fund (BCF)

Berkeley Catalyst Fund (BCF) investment in Series C - 4D Molecular Therapeutics

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series C - 4D Molecular Therapeutics

Official Site Inspections

http://www.4dmoleculartherapeutics.com Semrush global rank: 4.03 M Semrush visits lastest month: 3.04 K

Unable to get host informations!!!

Loading ...

More informations about "4D Molecular Therapeutics"

About | 4DMT - 4D Molecular Therapeutics

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market diseases.See details»

4D Molecular Therapeutics - Crunchbase Company …

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.See details»

Investors & Media | 4D Molecular Therapeutics

4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. 4DMT is striving to unlock the full potential of genetic medicines …See details»

4D Molecular Therapeutics - LinkedIn

4D Molecular Therapeutics | 15,822 followers on LinkedIn. Powering the Future of Genetic Medicines | 4DMT is a clinical stage biopharma company inventing and developing innovative products to ...See details»

Release Details - 4D Molecular Therapeutics

Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular degeneration (wet AMD), diabetic macular …See details»

Patients | 4DMT - 4D Molecular Therapeutics

4D-150 is being evaluated in the currently-enrolling PRISM clinical trial, a Phase 1/2 dose-escalation and randomized, controlled, masked expansion study of intravitreal 4D-150 in adults with wet AMD.The primary endpoints of the study …See details»

4D Molecular Therapeutics - Craft

Oct 4, 2024 4D Molecular Therapeutics has 5 employees at their 1 location and $20.72 m in annual revenue in FY 2023. See insights on 4D Molecular Therapeutics including office …See details»

Release Details - 4D Molecular Therapeutics

Oct 26, 2022 4D Molecular Therapeutics to host a conference call on November 3rd, 4:30 pm E.T. EMERYVILLE, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, …See details»

4D Molecular Therapeutics, Inc. (FDMT) - Yahoo Finance

Find the latest 4D Molecular Therapeutics, Inc. (FDMT) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»

Release Details - 4D Molecular Therapeutics

EMERYVILLE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed …See details»

4DMT Receives FDA Regenerative Medicine Advanced Therapy

Dec 21, 2023 4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First …See details»

Technology | 4DMT - 4D Molecular Therapeutics

Viruses have naturally evolved to infect cells and, in so doing, deliver their genetic contents into cells. Investigators in the field have engineered viruses for safety (removing their disease …See details»

Release Details - 4D Molecular Therapeutics

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed …See details»

4D Molecular Therapeutics, Inc. (FDMT) Stock Price, News, Quote ...

Find the latest 4D Molecular Therapeutics, Inc. (FDMT) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»

4D Molecular Therapeutics: Pioneering Gene Therapies …

Jul 10, 2023 Summary. 4D Molecular Therapeutics demonstrates a robust economic position and promising line-up of gene therapies, with a commitment to innovation and strategic …See details»

Release Details - 4D Molecular Therapeutics

Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating …See details»

Pipeline | 4DMT - 4D Molecular Therapeutics

4D-175 combines the customized and evolved intravitreal vector, R100, and a codon-optimized transgene encoding a highly functional shortened form of human complement factor H …See details»

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 …

Sep 19, 2024 4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow …See details»

Release Details - 4D Molecular Therapeutics

Feb 3, 2024 51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden (mean of 10 anti-VEGF …See details»

linkstock.net © 2022. All rights reserved